Last updated on April 21, 2014 at 8:43 EDT

Top Searched Stocks: JPMorgan, Pfizer, Illumina, CYS Investments, U.S. Bancorp, and Occidental Petroleum

October 16, 2012

VANCOUVER, British Columbia, Oct. 16, 2012 /PRNewswire/ — Insiderslab.com has issued insider trading reports and Equity Research for the following companies: JPMorgan (NYSE:JPM), Pfizer (NYSE:PFE), Illumina (NASDAQ:ILMN), CYS Investments (NYSE:CYS), U.S. Bancorp (NYSE:USB), and Occidental Petroleum (NYSE:OXY).

(Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO )

(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)

Report Highlights:

JPMorgan Chase & Co. (NYSE:JPM): Insiderslab.com found JPMorgan Chase & Co. (NYSE:JPM) Co-Chief Executive Officer, Investment Banking Division, Michael J. Cavanagh, sold 40,000 shares on October 15, at stock price US$42.00 for about US$1.68 million. Disclose date: October 15. In the last three months, JPMorgan officials have sold US$5.30 million in shares, while others have purchased US$17.11 million worth. JPMorgan last Friday reported net income was US$5.7 billion for the third quarter of 2012, compared with net income of US$4.3 billion in the third quarter of 2011. Earnings per share for the third quarter were US$1.40, up from US$1.02 in the same period last year. For the same quarter, revenue rose 6% to US$25.9 billion from a year ago. JPMorgan shares climbed 1.83% to US$42.38 on over 26.27 million shares, just above its average volume of 25.26 million shares. The company’s 52-week range remained US$28.28 to US$46.49 with its market capitalization touching US$161.03 billion. Insiderslab.com refers insider trading data to professional investors as it believes that JPMorgan insiders like Executive Officers and Directors have a better understanding about the company’s prospects. Do you want to know when JPMorgan insiders will buy their shares?

Read Full Report: http://www.insiderslab.com/PR3/101612A/JPM/JPMorgan.pdf

Pfizer Inc. (NYSE:PFE): In the last three months, Pfizer Inc. (NYSE:PFE) insiders have sold a total of US$365,980 in shares, at stock price US$24.01 each, according to insider trading report. On October 11, the biopharmaceutical company reported top-line results from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain. By the end of Monday’s trading, shares of Pfizer soared US$0.45 or 1.79% to US$25.57 and made a new 52-week high of US$25.62. Its price, as of the latest close, was up 40.9% compared with the 52-week low and was 0.2% below the 52-week high. PFE was traded above average volume with 30.91 million shares traded, 4.16 million shares more than its daily average. The company’s market capitalization after the recent close was US$190.99 billion. Investors may want to find out how Pfizer insiders like CEOs, CFOs and Directors are thinking about the future of the company. Check this insider trade report for PFE here.

Read Full Report: http://www.insiderslab.com/PR3/101612A/PFE/Pfizer.pdf

Illumina, Inc. (NASDAQ:ILMN): Insiderslab.com found company Senior Vice President, General Manager – Genetic Analysis, Christian O. Henry, sold 10,000 shares on October 9, at stock price US$51.70 for about US$516,960. Disclose date: October 11. In the last three months, company insiders have sold a total of US$2.42 million in shares, which ranged in price from US$45.00 to US$51.70 each. Last month, Illumina, Inc. (NASDAQ:ILMN) acquired Cambridge, U.K.-based BlueGnome Ltd. for an undisclosed sum. Illumina is scheduled to release its third-quarter 2012 financial results on Tuesday, October 23, 2012. Shares of Illumina began the trading session with a price of US$51.30 and throughout the session plunged to a low of US$46.50. When day-trade ended, the stock finally fell US$3.09 (or -6.04%) to US$48.07. Abnormal trading volume of Illumina was found reaching 7.10 million shares, 3.7 times heavier than usual day trading. Did Illumina insiders like CEOs, CFOs, and Directors sell their shareholdings before the stock price plunged? Academic studies have shown that insiders traditionally make higher investment returns than ordinary investors. Want to find out how they do it?

Read Full Report: http://www.insiderslab.com/PR3/101612A/ILMN/Illumina.pdf

Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.

CYS Investments Inc. (NYSE:CYS):

Read Full Report: http://www.insiderslab.com/PR3/101612A/CYS/CYSInvestments.pdf

U.S. Bancorp (NYSE:USB):

Read Full Report: http://www.insiderslab.com/PR3/101612A/USB/USBancorp.pdf

Occidental Petroleum Corporation (NYSE:OXY):

Read Full Report: http://www.insiderslab.com/PR3/101612A/OXY/OccidentalPetroleum.pdf

Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.

About Insiderslab.com:

Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore. Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.

Important Disclaimer:
Please visit insiderslab.com/disclaimers/disclaimers.php for details.

SOURCE Insiderslab.com; Insiders.hk

Source: PR Newswire